New Developments in Epilepsy Research

Article

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research.

AT AAN 2017, Andres Kanner, MD, Professor of Clinical Neurology, Chief of Epilepsy Division from the University of Miami Miller School of Medicine spoke with MD Magazine about the latest advancements in epilepsy research in all areas: genetics; variety of treatment modalities including epilepsy surgery and pharmacologic treatment; in our understanding of the pathogenic mechanisms associated with epilepsy.

“Neuro-imaging in epilepsy has transformed our way of evaluating patients both as far as evaluation for epilepsy surgery as well as understanding cognitive changes associated to those disorders. I particularly have been very interested in the development of a new surgical technique known as laser ablation that is MRI- guided as is used to treat people with temporal epilepsy or epilepsy that is associated with focal dysplasias.”

This surgical approach is not as invasive as a resection, and allows them to offer this treatment to patients that in the past were reluctant to consider surgical strategies. So far, this technique has been used in a greater number of epilepsy centers in the country and has been considered to be used outside of the US with some promise.

According to Kanner, the results obviously are limited being that they only have 1 or 2 years of follow up data, but so far that data looks quite promising. If these results are maintained for the next 5-10 years, then this could be a minimally invasive surgical approach that can replace some of the temporal resections that are typically done in epilepsy centers.

Related Videos
Evaluating MM120 for GAD with Daniel Karlin, MD, and Reid Robinson, MD, MBA
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
The Future of DSM-5-TR with APA Members Nitin Gogtay, Maria Oquendo, Jonathan Alpert
Ashkan Abbey, MD: 3-Year Efficacy of Pegcetacoplan for Geographic Atrophy | Image Credit: Texas Retina AssociatesImage Credit:
Clozapine and Second-Generation Antipsychotics for Schizophrenia, with John Kane, MD
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
John Kane, MD: Shifts in Antipsychotics for Schizophrenia
© 2024 MJH Life Sciences

All rights reserved.